Breaking News

The Philippines Launches ReCOV Vaccine Candidate Clinical Trial

January 17, 2022 • 7:05 am CST
(Precision Vaccinations News)

The Philippines announced today the authorization of the Recombinant COVID-19 Vaccine (ReCOV) developed by Jiangsu Recbio Technology Co., Ltd. ("Recbio") for Phase 2/3 clinical research.

Several preclinical research studies have shown that the ReCOV has a good neutralization effect on various SARS-CoV-2 variants such as Omicron and Delta. 

Recbio has submitted applications for Phase 2/3 clinical trials of the two-component ReCOV in several countries worldwide.

Based on the antigen design concept guided by neutralizing antibodies, the ReCOV vaccine adopts the two-component antigen of NTD-RBD-Foldon and is adjuvanted with self-developed BFA03(an AS03-like squalene adjuvant, which has a more potent immunogenicity and better neutralizing protective effect. 

Dr. Liu Yong, Chairman, and General Manager stated in a Recbio press release issued on January 17, 2022, "At present, to cope with mutant strains of immune escape effectively, it is urgent to accelerate the establishment of a strong immune barrier constructed by innovative COVID-19 vaccines."

"Based on ReCOV's strong Phase I immunogenicity and safety data, as well as good cross-neutralization against VOCs such as Omicron and Delta, we will accelerate international multi-center Phase II/III clinical development worldwide."

Recbio is an innovative vaccine development company located in Taizhou, China, and was founded in 2012. For more information, please visit https://www.recbio.cn/.

Our Trust Standards: Medical Advisory Committee

Share